Olanzapine: evaluation of thein vivocytogenetic effect
| Autor: | Papadopoulou Eleni, Zampas Constantinos, Antonis Goulas, Zafiroula Iakovidou-Kritsi |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Olanzapine medicine.medical_specialty medicine.drug_class Atypical antipsychotic medicine.disease Psychiatry and Mental health Neurology In vivo Schizophrenia Proliferation rate Relative risk Internal medicine medicine Pharmacology (medical) Neurology (clinical) Psychology Psychiatry medicine.drug |
| Zdroj: | Human Psychopharmacology: Clinical and Experimental. 30:189-192 |
| ISSN: | 0885-6222 |
| DOI: | 10.1002/hup.2471 |
| Popis: | Background/Aims Olanzapine (OLZ), an atypical antipsychotic, is licensed for use in the treatment of schizophrenia and other psychiatric disorders. Methods OLZ cytogenetic effects were investigated by evaluating the frequency of Sister Chromatid Exchanges (SCEs) and Proliferation Rate Index (PRI) in cultured lymphocytes of schizophrenic patients who were under treatment of OLZ. SCE estimation is one of the most sensitive biomarkers of potential cytotoxicity, while PRI is used as a valuable marker of cytostatic activity. Results Our results showed a statistically significant increase of SCEs in the cultured lymphocytes of patients (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|